Prothena Corp. and Novo Nordisk entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis program for as much as $1.2 billion, including $100 million in upfront and near-term clinical milestones. PRX004 is a phase 2-ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis. ATTR amyloidosis is a rare, progressive ...